



HAL
open science

Iterative fecal microbiota transplantations for eradicating digestive colonization with carbapenemase-producing Enterobacteriaceae: is it worth it?

Rafael Mahieu, Viviane Cassisa, Diane Sanderink, Rachel Chenouard, H el ene Pailhori es, Marie Kempf, Vincent Dub ee, Matthieu Eveillard

► To cite this version:

Rafael Mahieu, Viviane Cassisa, Diane Sanderink, Rachel Chenouard, H el ene Pailhori es, et al.. Iterative fecal microbiota transplantations for eradicating digestive colonization with carbapenemase-producing Enterobacteriaceae: is it worth it?. Infection Control and Hospital Epidemiology, 2017. inserm-01559275

HAL Id: inserm-01559275

<https://inserm.hal.science/inserm-01559275>

Submitted on 10 Jul 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destin ee au d ep ot et  a la diffusion de documents scientifiques de niveau recherche, publi es ou non,  emanant des  tablissements d'enseignement et de recherche fran ais ou  trangers, des laboratoires publics ou priv es.

Infection Control and Hospital Epidemiology

Iterative fecal microbiota transplantations for eradicating digestive colonization with carbapenemase-producing Enterobacteriaceae: is it worth it?

--Manuscript Draft--

Manuscript Number:	
Full Title:	Iterative fecal microbiota transplantations for eradicating digestive colonization with carbapenemase-producing Enterobacteriaceae: is it worth it?
Short Title:	
Article Type:	Letter
Corresponding Author:	Matthieu Eveillard, PharmD PhD CHU Angers Angers, FRANCE
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	CHU Angers
Corresponding Author's Secondary Institution:	
First Author:	Rafael Mahieu
First Author Secondary Information:	
Order of Authors:	Rafael Mahieu Viviane Cassisa Diane Sanderink Rachel Chenouard Hélène Pailhoriès Marie Kempf Vincent Dubée Matthieu Eveillard, PharmD PhD
Order of Authors Secondary Information:	
Abstract:	Carbapenemase-producing Enterobacteriaceae (CPE) have emerged as a major source of bacterial resistance and their dissemination is a serious public health threat. ¹ It has also been demonstrated that those bacteria could disseminate outside the hospital setting. A large study including 34 hospitals in Spain demonstrated that a significant proportion of patients identified as colonized or infected with CPE during hospitalization probably acquired this multi-resistant organism in a nursing home during the period preceding their hospital admission. ² In addition, a recent review of the literature demonstrated that according to US-based studies, the percentage of CPE isolates that could be associated with the community ranged from 5.6 to 10.8%. ³
Suggested Reviewers:	

**Iterative fecal microbiota transplantations for eradicating digestive colonization
with carbapenemase-producing Enterobacteriaceae: is it worth it?**

Rafael Mahieu, MD, MPH;¹ Viviane Cassisa, MPH;² Diane Sanderink, MD, MPH;¹
Rachel Chenouard, MD;^{1,2} H  l  ne Pailhori  s, PharmD, PhD;^{1,2} Marie Kempf,
PharmD, PhD;^{1,2} Vincent Dub  e, MD, PhD;^{1,3} Matthieu Eveillard, PharmD, PhD.^{1,2}

Affiliations :

1. Center for Research in Cancerology and Immunology Nantes-Angers, Institut National de la Sant   et de la Recherche M  dicale, Universit   de Nantes, Universit   d'Angers, Angers, France ; Equipe Atip-Avenir, Center for Research in Cancerology and Immunology Nantes-Angers, Institut National de la Sant   et de la Recherche M  dicale, Universit   de Nantes, Universit   d'Angers, Angers, France
2. Laboratoire de bact  riologie, CHU Angers, 4 rue Larrey, F-49933 Angers, France
3. Service des Maladies infectieuses et tropicales, CHU Angers, 4 rue Larrey, F-49933 Angers, France

Word count: 889

Keywords: fecal microbiota transplantation; mouse model; iterative administration; carbapenemase-producing Enterobacteriaceae; eradication

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

To the Editor - Carbapenemase-producing Enterobacteriaceae (CPE) have emerged as a major source of bacterial resistance and their dissemination is a serious public health threat.¹ It has also been demonstrated that those bacteria could disseminate outside the hospital setting. A large study including 34 hospitals in Spain demonstrated that a significant proportion of patients identified as colonized or infected with CPE during hospitalization probably acquired this organism in a nursing home during the period preceding their hospital admission.² In addition, a recent review of the literature demonstrated that according to US-based studies, the percentage of CPE isolates that could be associated with the community ranged from 5.6 to 10.8%.³

We have recently demonstrated the less effective effect of fecal microbiota transplantation (FMT) on CPE as compared to vancomycin-resistant Enterococci (VRE) fecal carriage.⁴ Those results are consistent with another recent study⁵ conducted in six patients colonized with CPE and showing an eradication of the colonization in only 2/6 patients. In these studies, the decolonization procedure included only one FMT. One hypothesis is that a protocol including iterative FMT separated each other by a several-day latency could increase the effectiveness of the procedure.

Our objective was to evaluate the impact of iterative MFT for the clearance of CPE carriage in our mouse model of digestive colonization.

Ethical approval was obtained from the Ethical Committee in Animal Experimentation of Pays-de-la-Loire, France (reference: 2015041415088410/APAFIS 513) and conducted according to European directives concerning the use of animals in research (86/609/EEC).

1
2 Twenty-eight 8-week old mice (Swiss type) were used for the model. The normal
3
4 digestive flora was disrupted with the daily oral administration of a combination of
5
6 antimicrobial agents including vancomycin (50 mg/kg), metronidazole (25 mg.kg) and
7
8 ceftriaxone (25 mg.kg) during 5 days (from day 1 to day 5). Mice were then
9
10 randomized to receive a high inoculum ($5 \cdot 10^9$ bacteria) of a strain of *Escherichia coli*
11
12 producing a New Delhi metallo- β -lactamase -1 (NDM-1). Those bacteria were
13
14 inoculated to the mice by oral gavage on day 4, day 5, and day 8. Mice were housed
15
16 in individual cages.
17
18
19

20
21 FMT was collected daily from related (Swiss mice of the same age) untreated mice.
22

23
24 Stool suspensions for FMT were prepared and stored as previously described.⁴ On
25
26 day 10, mice were randomized to receive FMT (14 mice) or placebo (14 mice).
27

28
29 During the experiment, 4 series of FMT or placebo administration were administered
30
31 to the mice. In each series, the mice received FMT or placebo once daily for three
32
33 successive days (from day 10 to day 12, from day 23 to day 25, from day 37 to day
34
35 39, and from day 49 to day 51) by oral gavage with 200 μ L of the stool suspension or
36
37 200 μ L of saline.
38
39

40
41 Stools were collected 3 times a week until day 57 and were weighted for quantitative
42
43 cultures. They were seeded on agar media (ChromID CARBA, bioMérieux, France)
44
45 after serial dilutions for CPE screening. Bacterial identification of CPE colonies was
46
47 controlled by using the MALDI-TOF technology (Vitek MS, bioMérieux). A mouse was
48
49 considered decolonized when 3 successive stool samples (corresponding to 4 or 5
50
51 days of follow-up) were found negative for CPE.
52
53

54
55 The evolution of the percentage of colonized mice during the follow-up period was
56
57 studied by the Kaplan-Meier analysis (SPSS software v15.0). The comparison
58
59

1 between the FMT group and the placebo group was performed by using the log-rank
2 test. The comparison of the percentage of colonized mice in each group at day 57
3
4 was performed with the Fisher exact test. A p value < 0.05 was considered
5
6 statistically significant.
7
8
9

10
11 The results are presented on figure 1. Overall, by considering the placebo effect
12 corresponding to the natural clearance of CPE digestive colonization of mice, the
13 iterative FMT series demonstrated a moderate impact on the decolonization kinetics
14 ($p = 0.22$). However, by considering the difference between the FMT protocol and the
15 placebo at the end of the follow-up period, the decolonization rates were more clearly
16 different (50% (7/14) and 21% (3/14) respectively), although this difference was not
17 significant ($p = 0.11$).
18
19
20
21
22
23
24
25
26
27
28
29
30

31 Due to the low number of mice included, this study only provides preliminary results.
32
33 Moreover, the uncertainty of reproduction in humans of what is demonstrated in
34 animals must be considered.
35
36
37

38 The iterative FMT allowed the eradication of CPE in 50% of colonized mice, which
39 can be considered as a moderately convincing result. In a recent study ⁶ conducted
40 with patients presenting blood disorders, the digestive carriage of NDM-1-producing
41 *Klebsiella pneumonia* was eradicated in less than 50% (6/14) of cases. In our
42 experiment, it is noteworthy that the decrease of the percentage of colonized mice
43 was higher in the FMT group than in the placebo group for each of the 4 treatment
44 series (figure 1). However, the short length of stay of most hospitalized patients limits
45 the applicability of a decolonization protocol including iterative FMT in the clinical
46 practice. However, it could be conceivable for patients hospitalized in long-term care
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 facilities or for the residents in nursing homes, in contexts of uncontrolled cross-
2 transmission during certain outbreaks of CPE carriage, and if the FMT are
3 administered orally. Additional studies are needed for evaluating the impact of the
4 composition of the transplanted fecal material on the FMT outcome in terms of CPE
5 eradication. Indeed, Ubeda et al.⁷ have recently demonstrated that intestinal
6 microbiota transplant containing *Barnesiella* species cured VRE colonization in mice.
7
8
9
10
11
12
13
14
15
16

17 **Conflict of interest statement**

18
19 No author declares conflict of interest.
20
21

22 **Financial support**

23
24
25
26 The study was supported by INSERM (Institut national de la santé et de la recherche
27 médicale) and by Angers University (programme « Année recherche 2015 »).
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

References

- 1
2 1. Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant
3
4 Enterobacteriaceae: the impact and evolution of a global menace. *J Infect Dis*
5
6 2017;215(Suppl. 1):S28-S36.
7
8
- 9
10 2. Palacios-Baena ZR, Oteo J, Conejo C, et al. Comprehensive clinical and
11
12 epidemiological assessment of colonization and infection due to carbapenemase-
13
14 producing Enterobacteriaceae in Spain. *J Infect* 2016;**72**:152-60.
15
16
- 17 3. Kelly AM, Mathema B, Larson EL. Carbapenem-resistant Enterobacteriaceae in
18
19 the community: a scoping review. *Int J Antimicrob Agents* 2017. doi:
20
21 10.1016/j.ijantimicag.2017.03.012.
22
23
- 24 4. Mahieu R, Cassisa V, Hilliquin D, et al. Impact of faecal microbiota transplantation
25
26 on mouse digestive colonization with two extensively resistant bacteria. *J Infect*
27
28 2017. doi: 10.1016/j.jinf.2017.04.008 (In press).
29
30
- 31 5. Davido B, Batista R, Michelon H, et al. Is faecal microbiota transplantation an
32
33 option to eradicate highly drug-resistant enteric bacteria carriage? *J Hosp Infect*
34
35 2017;**95**:433-7.
36
37
- 38 6. Bilinski J, Grzesiowski P, Sorensen N, et al. Fecal microbiota transplantation in
39
40 patients with blood disorders inhibits gut colonization with antibiotic-resistant
41
42 bacteria: results of a prospective, single-center study. *Clin Infect Dis* 2017. doi:
43
44 10.1093/cid/cix252.
45
46
- 47 7. Ubeda C, Bucci V, Caballero S, et al. Intestinal microbiota containing *Barnesiella*
48
49 species cures vancomycin-resistant *Enterococcus faecium* colonization. *Infect*
50
51 *Immun* 2013 ;**81** :965-73.
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 1: Comparative effect of iterative fecal microbiota transplantation and placebo administration on the digestive colonization with a carbapenemase-producing *Escherichia coli* in a mouse model.

